LEE'S PHARM (00950) · Company profile · Eqvero

LEE'S PHARM

00950HKEX

Unit: HKD	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.44 bn HKD	1.4 bn HKD	1.05 bn HKD	1.23 bn HKD	1.27 bn HKD
Cost of revenue	608.83 m HKD	547.31 m HKD	393.77 m HKD	336.87 m HKD	332.91 m HKD
Research and development expense	169.02 m HKD	132.26 m HKD	138.35 m HKD	195.86 m HKD	415.36 m HKD
Selling, general and administrative expense	556.96 m HKD	582.59 m HKD	492.91 m HKD	544.88 m HKD	663.7 m HKD
Operating profit after depreciation	110.28 m HKD	133.55 m HKD	36.04 m HKD	127.44 m HKD	-95.13 m HKD
Operating profit before depreciation	207.87 m HKD	232.85 m HKD	144 m HKD	252.97 m HKD	31.84 m HKD
EBIT	110.28 m HKD	133.55 m HKD	36.04 m HKD	127.44 m HKD	-95.13 m HKD
EBITDA	207.87 m HKD	232.85 m HKD	144 m HKD	252.97 m HKD	31.84 m HKD
Interest expense	10.85 m HKD	13.82 m HKD	11.28 m HKD	6.62 m HKD	4.4 m HKD
Profit before tax	72.89 m HKD	98.11 m HKD	30.79 m HKD	67.86 m HKD	1.97 bn HKD
Income tax expense	22.27 m HKD	29.5 m HKD	10.84 m HKD	22.03 m HKD	9.48 m HKD
Income before extraordinary items	91.94 m HKD	93.1 m HKD	16.7 m HKD	51.28 m HKD	1.99 bn HKD
Common dividends	26.5 m HKD	26.5 m HKD	10.6 m HKD	11.78 m HKD	35.92 m HKD
Total dividends	26.5 m HKD	26.5 m HKD	10.6 m HKD	11.78 m HKD	35.92 m HKD

Quotes are end-of-day data. Content is for research purposes and is not investment advice.